Revvity sells life sciences research tools, reagents and instruments to drug developers, researchers and academic labs, and it also has a diagnostics business. RVTY reports earnings on Tue, Nov 3, 2026. Analyst consensus is Buy, based on the latest ratings from 6 firms (3 buy, 3 hold, 0 sell). Over the past 90 days StreetAlpha recorded 1 whale options trade in RVTY, 0% of them bullish and 100% bearish. In the past 30 days there were 8 dark pool prints.
Prices, price targets and earnings estimates for RVTY are shown to AI Starter and AI Pro members. Ratings, flow and news are open to everyone.See plansSign in
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether RVTY is in one of them and how their past RVTY trades turned out.
Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.
About Revvity
Revvity is a health science company based in Waltham, Massachusetts. Its Life Sciences business sells reagents, assay kits, antibodies, cell lines and instruments such as plate readers and drug screening systems. Its customers include pharmaceutical, biotech and contract research companies, along with academic and government institutions. The company also reports a separate Diagnostics segment.
